Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
NanoLogix, Inc. (NNLX)
Hubbard, OH, US
NanoLogix, Inc., a biotechnology firm, specializes in developing and providing rapid diagnostic and live cell test kits. These kits are designed to accurately detect viable bacteria and a wide array of other microorganisms. Among its key offerings are the BioNanoPore kit, which utilizes a unique water-permeable membrane capable of interacting with organic, inorganic molecules, and proteins. Another significant product is the FlatPack Petri Plate, essential for the isolation and cultivation of diverse microorganisms, including both fastidious and non-fastidious types, as well as those requiring or not requiring oxygen for growth (aerobic and anaerobic respectively). The company's solutions are applied across a broad spectrum of sectors, including medical diagnostics, national defense, homeland security initiatives, pharmaceutical research and manufacturing, industrial processes, veterinary science, and environmental monitoring. NanoLogix serves an established clientele comprising prominent medical and scientific organizations. This includes laboratories, healthcare institutions, academic universities, various businesses, and specialized research establishments. Headquartered in Hubbard, Ohio, NanoLogix, Inc. operates from this location.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +9,900.00% | +0.00% | +0.00% | -99.54% | -99.69% | -99.97% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Biotechnology: +1.6%-59.7%
-
EPS growth Biotechnology: +29.7%+29.2%
-
FCF margin FCF growth · Biotechnology: +16.2%-3,302.4%
-
EBIT margin Biotechnology: +0.0%-3,626.8%
-
ROIC Biotechnology: -16.1%-182.5%
-
Share dilution Biotechnology: -3.4%+4.2%
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.08×
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bret T. Barnhizer | Chairman, Chief Executive Officer & President | — | male |
| Carol J. Surrena | Corporate Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NNLX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
